Detailed Information

Cited 1 time in webofscience Cited 2 time in scopus
Metadata Downloads

Plasma Aldo-Keto Reductase Family 1 Member B10 as a Biomarker Performs Well in the Diagnosis of Nonalcoholic Steatohepatitis and Fibrosisopen access

Authors
Park, AronChoi, Seung JoonPark, SungjinKim, Seong MinLee, Hye EunJoo, MinjaeKim, Kyoung KonKim, DoojinChung, Dong HaeIm, Jae BeenJung, JaehunShin, Seung KakOh, Byung-ChulChoi, CheolsooNam, SeungyoonLee, Dae Ho
Issue Date
May-2022
Publisher
MDPI
Keywords
nonalcoholic fatty liver disease; aldo-keto reductase family 1 member B10; biomarkers; diagnosis
Citation
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, v.23, no.9
Journal Title
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume
23
Number
9
URI
https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/84418
DOI
10.3390/ijms23095035
ISSN
1661-6596
Abstract
We found several blood biomarkers through computational secretome analyses, including aldo-keto reductase family 1 member B10 (AKR1B10), which reflected the progression of nonalcoholic fatty liver disease (NAFLD). After confirming that hepatic AKR1B10 reflected the progression of NAFLD in a subgroup with NAFLD, we evaluated the diagnostic accuracy of plasma AKR1B10 and other biomarkers for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis in replication cohort. We enrolled healthy control subjects and patients with biopsy-proven NAFLD (n = 102) and evaluated the performance of various diagnostic markers. Plasma AKR1B10 performed well in the diagnosis of NASH with an area under the receiver operating characteristic (AUROC) curve of 0.834 and a cutoff value of 1078.2 pg/mL, as well as advanced fibrosis (AUROC curve value of 0.914 and cutoff level 1078.2 pg/mL), with further improvement in combination with C3. When we monitored a subgroup of obese patients who underwent bariatric surgery (n = 35), plasma AKR1B10 decreased dramatically, and 40.0% of patients with NASH at baseline showed a decrease in plasma AKR1B10 levels to below the cutoff level after the surgery. In an independent validation study, we proved that plasma AKR1B10 was a specific biomarker of NAFLD progression across varying degrees of renal dysfunction. Despite perfect correlation between plasma and serum levels of AKR1B10 in paired sample analysis, its serum level was 1.4-fold higher than that in plasma. Plasma AKR1B10 alone and in combination with C3 could be a useful noninvasive biomarker for the diagnosis of NASH and hepatic fibrosis.
Files in This Item
There are no files associated with this item.
Appears in
Collections
바이오나노대학 > 생명과학과 > 1. Journal Articles
의과대학 > 의예과 > 1. Journal Articles
의과대학 > 의학과 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Chung, Dong Hae photo

Chung, Dong Hae
College of Medicine (Premedical Course)
Read more

Altmetrics

Total Views & Downloads

BROWSE